Pubblicazioni
Crediamo fortemente nel valore della divulgazione scientifica, come strumento di conoscenza e progresso.
Dal 2009 i risultati delle nostre sperimentazioni cliniche vengono pubblicate su importati riviste di settore e presentati a numerosi congressi internazionali.
Pubblicazioni su riviste scientifiche
Niente nella vita va temuto, dev’essere solamente compreso. Ora è tempo di comprendere di più, così possiamo temere di meno. Marie Curie
Oliva EN, Cuzzola M, Nobile F, et al. (2010).
Changes in RPS14 expression levels during lenalidomide treatment in Low-and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J. Haematol, 85:231-5.
Oliva EN, Nobile F, Alimena G, et al. (2010). Darbepoetin For The Treatment Of Anemia Of Myelodysplastic Syndromes: Efficacy And Quality Of Life. Leukemia and Lymphoma, 51(6):1007-14.
Breccia M, Cannella L, Latagliata R, et al. (2011). Unexpected erythroid and cytogenetic responses after discontinuation of short course of lenalidomide due to severe skin rash in a 5q syndrome patient. J Clin Oncol, May 10;29(14): e 402-3.
Breccia M, Cannella L, Latagliata R, et al. (2011). Sudden acute leukemia transformation in a MDS patient with del (5q) in complete cytogenetic remission after lenalidomide. Leuk Res., 35, 690.
Cannella L, Latagliata R, Breccia M, et al. (2012). Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, Feb; 91 (2):309-10.
Oliva EN, Cuzzola M, Poloni A, et al. (2013). Biological activity of lenalidomide in myelodysplastic sindromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol., Jan;92(1):25-32.
Oliva EN, Latagliata R, Laganà C, et al. (2013). Lenalidomide in Low-and intermediate-1 IPSS risk myelodysplastic sindromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and efficacy. Leuk Linphoma., Nov;54(11):2458-65.
Oliva EN, Lauseker M, Aloe Spiriti MA, at al. (2015). Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med., Dec; 4(12):1789-97.
Oliva EN, Alati C, Santini V, et al. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol., Mar;4(3): e127-e136. doi: 10.1016/S2352-3026(17)30012-1.
Oliva EN, Latagliata R, Sabattini E, et al. (2021) Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. Am J Blood Res., 11(4): 417–426
Presentazioni a Congressi
Oliva EN, Cuzzola M, Iacopino P, et al. (2009). Gene expression patterns in MDS with del5q before and during Lenalidomide treatment. MDS International Symposium, Patrasso, Grecia, maggio 2009. Leuk Res, supplement, 2009.
Oliva EN, Latagliata R, Morabito F, et al. (2009). Lenalidomide for the treatment of Low- and Int-1-Risk MDS with Del(5q): efficacy and quality of life study. 51th ASH Annual Meeting; Blood 2009 114:2763 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 dicembre 2009
Oliva EN; Cuzzola M, Latagliata R, et al. (2009). Gene expression changes in bone marrow of MDS patients with Del(5q) during Lenalidomide treatment. 51th ASH Annual Meeting; Blood 2009 114:2622 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 dicembre 2009
Oliva EN, Nobile F, Alimena G, et al. (2011). Quality of life in elderly patients with Acute Myeloid Leukemia: patients may be more accurate than physicians. 16th Congresso EHA; Haematologica May 2011 96: 696-702; Londra, UK, 9-12 giugno 2011
Oliva EN, Latagliata R, Aloe Spiriti MA, et al. (2011). Clinically meaningful responses in low risk MDS patients with del5q treated with lenalidomide: quality of life and cardiac changes. Leukemia Research 35 (2011) S27–S142. 11th Simposio Internazionale sulle Sindromi Mielodisplastiche (MDS), 18-21 maggio 2011, Edinburgo, UK
Oliva EN, Nobile F, Alimena G, et al. (2011). Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011, maggio; 96(5):696-702
Oliva EN; Santini V, Zini G, et al. (2012). Efficacy and safety of Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS). 54thASH Annual Meeting. Blood, vol. 120:923, ISSN: 1528-0020, Atalanta (Georgia) USA, 9-12 dicembre 2012
Oliva EN, Santini V, Zini G, et al. (2013). Eltrombopag for the treatment of Low and Intermediate -1 IPSS Risk Myelodyslastic Syndromes: results of a prospective, randomized, trial. 18th Congresso EHA; Haematologica June 2013 98: (s1); Stoccolma, Svezia, 13-16 giugno 2013
Oliva EN, Santarone S, Leoni P, et al. (2013). A randomized open-label study to evaluate the efficacy of Azacitidine for post-remission therapy of Acute Myeloid Leukemia in elderly patients (QoLESS AZA-AMLE). 55th ASH Annual Meeting; Blood 2013 122:3967 ISSN: 1528-0020; New Orleans (Louisiana)USA, 7-10 dicembre 2013
Oliva EN, Lauseker M, Aloe Spiriti MA, et al. (2014). Clinical benefit of Lenalidomide treatment for Low and Intermediate -1 IPSS Risk Myelodysplastic Syndromes with Del(5q) before transfusion dependence. 19th Congresso EHA; S1331; 99(s1) Haematologica 2014. Milano, Italia, giugno12-15 2014
Oliva EN, Alati C, Salutari P, et al. (2014). Azacitidine as post-remission therapy in elderly patients with Acute Myeloid Leukemia significantly prolongs disease-free survival: interim results from a prospective, randomized, open-label, phase III multicenter trial. 56th ASH Annual Meeting Blood (2014) Poster 124 (21): 2299. San Francisco (California) USA, 6-9 dicembre 2014
Oliva EN, Santini V, Alati C, et a. (2015). Quality of life in patients with lower risk Myelodysplastic Syndromes with severe thrombocytopenia treated with Eltrombopag: Interim results of a randomized, placebo controlled prospective trial. 20th Congresso EHA; Haematologica vol. 100 ISSN: 0390-6078; Vienna, Austria, 11-14 giugno 2015
Oliva EN, Santini V, Alati C, et al. (2015). Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. 57th ASH Annual Meeting; Blood 2015 126:91 ISSN: 1528-0020¸ Orlando (Florida) USA, 5 – 8 dicembre 2015
Oliva EN, Salutari P, Candoni A, et al. (2015). Quality of life in elderly patients with Acute Myeloid Leukemia undergoing induction chemotherapy. 57th ASH Annual Meeting; Blood 2015 126:2120 ISSN: 1528-0020; Orlando (Florida) USA, 5 – 8 dicembre 2015
Oliva EN, Santini V, Alati C, et al. (2015). Quality of life in patients with lower risk Myelodysplastic Syndromes with severe thrombocytopenia treated with Eltrombopag: interim results of a randomized, placebo controlled prospective trial. 20th Congresso EHA; Haematologica vol. 100 ISSN: 0390-6078; Vienna, Austria, 11-14 giugno 2015
Oliva EN, Santini V, Alati C, et al. (2015). Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. In: 57th ASH Annual Meeting; Blood 2015 126:91 ISSN: 1528-0020; Orlando (Florida) USA, 5 -8 dicembre 2015
Cuzzola M, Alati C, Di Bartolomeo P, et al. (2016). Biological markers of relapse in elderly patients with AML in CR after induction-consolidation chemotherapy and manteinance with 5-Azacitidine. 21th Congresso EHA; EHA Library. Jun 9, 2016; Poster 132455; E906. Copenhagen, Danimarca, 9-12 giugno 2016
Oliva EN; Martino B, Salutari P, et al. (2018). Randomized open-label, phase III multicenter trial to evaluate Azacitidine post -remission therapy in elderly patients with Acute Myeloid Leukemia. 23th Congresso EHA; EHA Learning Center. OLIVA E. Jun 16, 2018; 215308; Stoccolma, Svezia, 14-17 giugno 2016
Di Rocco M, Cappellini MA, Carubbi F, et al. (2018). Observational study to develop treatment- related patient reported outcome measure in Gaucher disease (QOL-ONE PRO 1G). 23th Congresso EHA; EHA Learning Center. OLIVA E. Jun 14, 2018; 216144¸ Abstract: PB2398; Stoccolma, Svezia, 14-17 giugno 2016
Oliva EN, Candoni A, Salutari P, et al. (2019). Azacitidine for post remission therapy in elderly patients with Acute Myeloid Leukemia: final results of the Qoless AZA-AMLE randomized trial. 61th ASH Annual Meeting; Orlando (Florida), Usa, 7-10, dicembre 2019
Oliva EN, Alati C, Santini V, et al. (2019). Long term effects of Eltrombopag treatment versus placebo for low-risk Myelodysplastic Syndromes with thrombocytopenia (EQoL-MDS): interim results of a single-blind, randomized, controlled, phase 2 superiority trial. 61th ASH Annual Meeting; Orlando (Florida), Usa, 7-10, dicembre 2019
Oliva EN, Mammi’ C, Cuzzola M, et al. (2021). NGS evaluation of the Eqol-MDS trial: preliminary analysis of Eltrombopag for thrombocytopenia of low-risk MDS. 63th ASH Annual Meeting; Atlanta, Georgia, dicembre 11-14 2021
Urciuoli E, Di Bona E, Greve S, et al. (2022). Observational study to evaluate patient – reported outcomes in Paroxysmal Nocturnal Hemoglobinuria. 26th Congresso EHA. Poster Quality of life, palliative care, ethics and health economics EHA-2996. 26th Congresso EHA; Vienna, Austria, 9-12 giugno 2022
Oliva EN, Salutari P, Di Raimondo F, et al. (2022) Final results of the QoLESS AZA–AMLE randomized trial to evaluate the efficacy of 5- Aza for post-remission therapy of Acute Myeloid Leukemia in elderly patients. Poster 04. Acute myeloid leukemia – Clinical EHA; 26th Congresso EHA; Vienna, Austria, 9-12 giugno 2022
Aiutaci a migliorare il nostro servizio
Dona Adesso
Address
123 5th Avenue, New York, US
Call Us
+1 123 456 7890
Email Us
info@example.com